Literature DB >> 4007030

Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.

S Almog, N Shafran, H Halkin, P Weiss, Z Farfel, U Martinowitz, H Bank.   

Abstract

Potentiation of the anticoagulant-effect of warfarin by amiodarone was studied in 30 patients. Thirteen received both drugs concurrently, and 17 received warfarin alone and the combination sequentially. Warfarin doses were adjusted to maintain the prothrombin time between 25-30% of control and its kinetics were compared to those in 20 control patients who received warfarin alone. Potentiation occurred in 28/30 patients, presenting as a 35%-65% reduction in the required dose of warfarin, and was correlated with the dose of amiodarone (r = 0.77, p less than 0.01). The free warfarin fraction was not affected by amiodarone (1.8% vs 1.6% in the controls). Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p less than 0.01) with similar plasma concentrations (1.5 vs 1.2 micrograms/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively). The amiodarone concentration was significantly correlated with the warfarin concentrations independent of the effect of amiodarone on the dose of warfarin. Amiodarone hat no effect on prothrombin other than through its actions on the dose and plasma concentration of warfarin. The mechanism of the amiodarone-warfarin interaction is pharmacokinetic through dose - and concentration - dependent inhibition of warfarin elimination.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007030     DOI: 10.1007/bf00543320

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Drug interactions with amiodarone.

Authors:  F I Marcus
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

3.  Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience.

Authors:  C I Haffajee; J C Love; J S Alpert; G K Asdourian; K C Sloan
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

4.  Dangers of amiodarone and anticoagulant treatment.

Authors:  M J Serlin; R G Sibeon; G J Green
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-04

5.  Dangers of amiodarone and anticoagulant treatment.

Authors:  A Rees; J J Dalal; P G Reid; A H Henderson; M J Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

6.  High-pressure liquid chromatography of amiodarone in biological fluids.

Authors:  L J Lesko; A Marion; A T Canada; C Haffajee
Journal:  J Pharm Sci       Date:  1981-12       Impact factor: 3.534

7.  Comparison of high-performance liquid chromatography and a spectrophotometric technique for determining plasma warfarin.

Authors:  W B Forman; J Shlaes
Journal:  J Chromatogr       Date:  1978-11-01

8.  Interaction between warfarin sodium and amiodarone.

Authors:  U Martinowitz; J Rabinovich; D Goldfarb; A Many; H Bank
Journal:  N Engl J Med       Date:  1981-03-12       Impact factor: 91.245

9.  The potentiation of warfarin anticoagulation by amiodarone.

Authors:  A Hamer; T Peter; W J Mandel; M M Scheinman; D Weiss
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

10.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

  10 in total
  15 in total

1.  The use of wireless laptop computers for computer-assisted learning in pharmacokinetics.

Authors:  Myrna Y Munar; Harleen Singh; Donna Belle; Carolyn C Brackett; Sandra B Earle
Journal:  Am J Pharm Educ       Date:  2006-02-15       Impact factor: 2.047

2.  The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.

Authors:  Shi-Long Zhong; Yuan Liu; Xi-Yong Yu; Dan Xu; Hong-Hong Tan; Qiu-Xiong Lin; Min Yang; Hai-Yan Lao; Shu-Guang Lin
Journal:  Eur J Clin Pharmacol       Date:  2011-02-12       Impact factor: 2.953

3.  Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.

Authors:  D S Dhanda; G F Guzauskas; J J Carlson; A Basu; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2017-07-10       Impact factor: 6.875

Review 4.  Amiodarone-associated optic neuropathy: a critical review.

Authors:  Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy
Journal:  Am J Med       Date:  2012-03-03       Impact factor: 4.965

5.  Prescribing warfarin appropriately to meet patient safety goals.

Authors:  Lekshmi Dharmarajan; T S Dharmarajan
Journal:  Am Health Drug Benefits       Date:  2008-07

Review 6.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 8.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 9.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.

Authors:  A Choppin; I Irwin; L Lach; M G McDonald; A E Rettie; L Shao; C Becker; M P Palme; X Paliard; S Bowersox; D M Dennis; P Druzgala
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.